Gossamer Bio Stock Price, News & Analysis

Gossamer Bio, Inc. (GOSS) announced that Chief Scientific Officer Luisa Salter-Cid will resign effective April 30, 2021. Laura Carter, previously Senior Vice President of Research & Translational Biology, will succeed her. Chairman and CEO Faheem Hasnain acknowledged Salter-Cid's contributions in developing the pre-clinical pipeline and welcomed Carter, highlighting her extensive experience in immunology and clinical development. Carter's background includes leadership roles in various biopharmaceutical firms, enhancing her capability to drive Gossamer’s clinical programs forward.

Gossamer Bio (Nasdaq: GOSS) has promoted Caryn Peterson to Executive Vice President, Regulatory Affairs, effective immediately. In her new role, Peterson will lead the company's regulatory and quality functions and develop global regulatory strategies for clinical and pre-clinical programs. She has been with Gossamer since 2018, previously serving as Senior Vice President, Regulatory & Quality. CEO Faheem Hasnain highlighted her strategic acumen and strong relationships with regulatory agencies as vital for advancing Gossamer's clinical portfolio, which includes candidates like seralutinib and GB004.

Gossamer Bio, Inc. (Nasdaq: GOSS) reported its financial results for Q4 and the full year 2020, reflecting a net loss of $64.6 million for the quarter and $243.4 million for the year. R&D expenses for Q4 were $38.9 million, down from $42.6 million in 2019, while full-year R&D expenses increased to $160.9 million. The company has $512.6 million in cash and equivalents, expected to fund operations into 2023. Notable clinical trials include seralutinib for PAH and GB004 for IBD, with data expected in 2022.

Gossamer Bio, a clinical-stage biopharmaceutical company (Nasdaq: GOSS), announced it will report its fourth quarter and full-year 2020 financial results on February 25, 2021. A conference call and webcast will follow at 8:30 a.m. ET that same day, providing an update on the financial results and corporate developments. Investors can access the live webcast via the company's website. Gossamer Bio is dedicated to developing therapeutics in immunology, inflammation, and oncology, aiming to become a leader in these fields.

Gossamer Bio, a clinical-stage biopharmaceutical company (Nasdaq: GOSS), has announced a conference call and webcast on February 18, 2021, at 11:00 am ET. The event will discuss GB004, their oral HIF-1α stabilizer aimed at treating inflammatory bowel disease (IBD), specifically ulcerative colitis (UC). Esteemed experts in the field, including William Sandborn, Silvio Danese, and Cormac Taylor, will join Gossamer management for insights and a Q&A session. The webcast will be available on the company's website, and a replay will be accessible for 30 days.

Gossamer Bio, a clinical-stage biopharmaceutical company (Nasdaq: GOSS), announced a conference call and webcast on December 15, 2020, at 11:00 am ET to discuss GB002, an inhaled PDGFR inhibitor intended for treating pulmonary arterial hypertension (PAH). The event will feature insights from leading experts in PAH, Dr. Lewis Rubin and Dr. Vallerie McLaughlin. The session aims to cover GB002's development and its significance in addressing unmet therapeutic needs in PAH. The conference call can be accessed via the company's website.

Gossamer Bio has appointed Faheem Hasnain as Chief Executive Officer and President, succeeding Sheila Gujrathi, who served in the role since July 2018. Hasnain, a co-founder, previously led Receptos, Inc. before its acquisition by Celgene. In his new role, Hasnain aims to advance Gossamer's therapeutic pipeline in immunology, inflammation, and oncology. Dr. Gujrathi will remain as an advisor. The transition occurs as the company navigates the complexities of clinical-stage biopharmaceutical development, with a focus on unmet patient needs.

Gossamer Bio, Inc. (Nasdaq: GOSS) reported its Q3 2020 financial results, highlighting ongoing advancements in its clinical trials for GB002, GB004, and GB1275. GB002's Phase 2 trial for pulmonary arterial hypertension is set to enroll patients in Q4 2020, with topline data expected in H1 2022. GB004 is in a Phase 2 trial for inflammatory bowel disease, also targeting H1 2022 for topline data. Financially, Gossamer holds $555.4 million in liquid assets but reported a $57.8 million net loss for the quarter, influenced by increased interest expenses.

Gossamer Bio, Inc. (GOSS) will report its third quarter 2020 financial results on November 10, 2020. A live conference call will take place at 4:30 p.m. ET, allowing the management team to discuss the financial results and provide corporate updates. Interested parties can join the call using the domestic number (833) 646-0603 or international number (929) 517-9782. A subsequent audio webcast will be available for 30 days on their website.